Sanjivani Paranteral Ltd vs Sun Pharmaceutical Industries Ltd

A side-by-side comparison of Sanjivani Paranteral Ltd (SANJIVIN) and Sun Pharmaceutical Industries Ltd (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Ltd leads SANJIVIN vs SUNPHARMA on 8 of 14 metrics (2 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

21.81
P/E ratio
41.01
3.75
P/B ratio
5.60
0.34%
Dividend yield
0.82%
₹6.81
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

20.30%
Return on equity
16.00%
28.46%
Return on capital
21.00%
14.75%
EBITDA margin
30.00%
11.54%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

Revenue CAGR (3Y)
10.03%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹189 Cr
Market cap
₹4.67L Cr
₹70 Cr
Revenue
₹58,462 Cr
₹8 Cr
Net profit
₹11,509 Cr
0.30
Debt / equity
0.06
Sanjivani Paranteral Ltd
  • ["Promoter holding is low: 31.6%", "Company might be capitalizing the interest cost", "Debtor days have increased from 66.8 to 82.0 days."]
Sun Pharmaceutical Industries Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Sanjivani Paranteral Ltd full analysis Sun Pharmaceutical Industries Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

Sanjivani Paranteral Ltd vs Sun Pharmaceutical Industries Ltd: Share Price, Valuation & Which to Buy | DocStoX